Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.71 |
| ▸ | GRIN2D | O15399 | 5/20 | 0.71 |
| ▸ | GRIN3B | O60391 | 5/20 | 0.71 |
| ▸ | GRIN1 | Q05586 | 5/20 | 0.71 |
| ▸ | GRIN2A | Q12879 | 5/20 | 0.71 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.71 |
| ▸ | GRIN2C | Q14957 | 5/20 | 0.71 |
| ▸ | GRIN3A | Q8TCU5 | 5/20 | 0.71 |
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.71 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.71 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.71 |
| ▸ | ADRA2A | P08913 | 5/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL809224 | 0.84 | SIGMAR1 (1.00) | SIGMAR1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL78658 | 0.84 | SIGMAR1 (1.00) | SIGMAR1GRIN2DGRIN3BGRIN1GRIN2A | |
| Bromide SCHEMBL30258978 | 0.82 | SIGMAR1 (0.96) | SIGMAR1GRIN2DGRIN3BGRIN1GRIN2A | |
| Hydrochloric Acid SCHEMBL8157616 | 0.82 | SIGMAR1 (0.96) | SIGMAR1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL5574678 | 0.81 | MEN1 (0.65) | SIGMAR1LMNAKMT2ATDP1NOS1 | |
| SCHEMBL27003076 | 0.79 | SIGMAR1 (0.76) | SIGMAR1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL27003083 | 0.79 | SIGMAR1 (0.76) | SIGMAR1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL27003079 | 0.79 | SIGMAR1 (0.83) | SIGMAR1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL2746644 | 0.79 | CA2 (0.50) | LMNAKMT2ATDP1CA12CA1 | |
| SCHEMBL7296946 | 0.79 | ALDH1A1 (0.50) | LMNAKMT2ATDP1CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190000862-A1 | METHODS AND SYSTEMS FOR THE DELIVERY OF A THERAPEUTIC AGENT | HANANJA EHF (IS) | 2019-01-03 | — | — | US | claimed |
| US-20190000862-A1 | METHODS AND SYSTEMS FOR THE DELIVERY OF A THERAPEUTIC AGENT | HANANJA EHF (IS) | 2019-01-03 | — | — | US | disclosed |
| US-10052333-B2 | Methods and systems for the delivery of a therapeutic agent | UNIVERSITY OF ICELAND (IS) | 2018-08-21 | — | — | US | disclosed |
| US-20180000834-A1 | METHODS AND SYSTEMS FOR THE DELIVERY OF A THERAPEUTIC AGENT | HANANJA EHF | 2018-01-04 | — | — | US | disclosed |
| US-9687495-B2 | Methods and systems for the delivery of a therapeutic agent | HANANJA EHF (IS) | 2017-06-27 | — | — | US | disclosed |
| EP-3150230-A1 | METHODS AND COMPOSITIONS FOR THE DELIVERY OF A THERAPEUTIC AGENT | Hananja Ehf (IS) | 2017-04-05 | — | — | EP | disclosed |
| EP-2121025-B1 | METHODS AND COMPOSITIONS FOR THE DELIVERY OF A THERAPEUTIC AGENT | HANANJA EHF (IS) | 2016-11-02 | — | — | EP | disclosed |
| US-20160158248-A1 | METHODS AND SYSTEMS FOR THE DELIVERY OF A THERAPEUTIC AGENT | HANANJA EHF | 2016-06-09 | — | — | US | disclosed |
| US-9289432-B2 | Methods and compositions for the delivery of a therapeutic agent | HANANJA EHF and UNIVERSITY OF ICELAND (IS) | 2016-03-22 | — | — | US | disclosed |
| US-20140323472-A1 | METHODS AND COMPOSITIONS FOR THE DELIVERY OF A THERAPEUTIC AGENT | HANANJA EHF (IS) | 2014-10-30 | — | — | US | disclosed |
| US-20090227568-A1 | METHODS AND COMPOSITIONS FOR THE DELIVERY OF A THERAPEUTIC AGENT | HANANJA EHF (IS) | 2009-09-10 | — | — | US | disclosed |
| US-20080286377-A1 | ANTI-RESORPTIVE BONE CEMENTS AND ALLOGENEIC, AUTOGRAFIC, AND XENOGRAFIC BONE GRAFTS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2008-11-20 | — | — | US | disclosed |
| US-20080275030-A1 | alkoxy-polyethylene glycol or (ethylene oxide)1-10 adduct of methanol, ethanol, propanol, isopropanol and cyclopropanol; benzodiazepine; midazolam as a liqid therapeutic agent; less irritation to mucosal membrane when administered through Mucosal; enhances solubility of drug | IKANO THERAPEUTICS, INC. (FORMERLY KNOWN AS "INTRANASAL THERAPEUTICS, INCORPORATED") | 2008-11-06 | — | — | US | disclosed |
| WO-2000047214-A9 | ANTI-RESORPTIVE BONE CEMENTS AND ALLOGENEIC, AUTOGRAFIC, AND XENOGRAFIC BONE GRAFTS | SLOAN KETTERING INST CANCER (US) | 2002-04-11 | — | — | WO | disclosed |
| EP-0532546-B1 | A PHARMACEUTICAL PREPARATION CONTAINING N-GLYCOFUROLS AND N-ETHYLENE GLYCOLS | BECHGAARD INT RES (DK) | 1998-03-18 | — | — | EP | disclosed |
| US-5693608-A | ABSORPTION OF DRUG DELIVERED IN ETHYLENE OXIDE ADDUCT VEHICLE THROUGH NASAL MUCOUS MEMBRANES | BECHGAARD INTERNATIONAL RESEARCH AND DEVELOPMENT A/S (DK) | 1997-12-02 | — | — | US | disclosed |
| US-5428006-A | Including an n-glycofurol; improves absorption through mucous membranes | BECHGAARD INTERNATIONAL RESEARCH AND DEVELOPMENT A/S (DK) | 1995-06-27 | — | — | US | disclosed |
| US-5397771-A | As vehicle for application of biologically active substances to mucosal membranes of mammals, dissolved or suspended | BECHGAARD INTERNATIONAL RESEARCH AND DEVELOPMENT A/S (DK) | 1995-03-14 | — | — | US | disclosed |
| EP-0532546-A1 | A PHARMACEUTICAL PREPARATION CONTAINING N-GLYCOFUROLS AND N-ETHYLENE GLYCOLS | BECHGAARD INTERNATIONAL RESEARCH AND DEVELOPMENT A/S (DK) | 1993-03-24 | — | — | EP | disclosed |
| WO-1991016929-A1 | A PHARMACEUTICAL PREPARATION CONTAINING N-GLYCOFUROLS AND N-ETHYLENE GLYCOLS | NOVO NORDISK A/S (DK) | 1991-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10052333-B2 | Methods and systems for the delivery of a therapeutic agent | TMEM205, NUP205, PIGS | SIGMAR1 1703/4885GRIN2D 4670/4885GRIN3B 2626/4885 |
| US-20160158248-A1 | METHODS AND SYSTEMS FOR THE DELIVERY OF A THERAPEUTIC AGENT | TMEM205, NUP205, PIGS | SIGMAR1 1703/4885GRIN2D 4670/4885GRIN3B 2626/4885 |
| US-20180000834-A1 | METHODS AND SYSTEMS FOR THE DELIVERY OF A THERAPEUTIC AGENT | TMEM205, NUP205, PIGS | SIGMAR1 1703/4885GRIN2D 4670/4885GRIN3B 2626/4885 |
| US-20190000862-A1 | METHODS AND SYSTEMS FOR THE DELIVERY OF A THERAPEUTIC AGENT | TMEM205, NUP205, PIGS | SIGMAR1 1703/4885GRIN2D 4670/4885GRIN3B 2626/4885 |
| US-20090227568-A1 | METHODS AND COMPOSITIONS FOR THE DELIVERY OF A THERAPEUTIC AGENT | TMEM205, NUP205, PIGS | SIGMAR1 1624/4885GRIN2D 4570/4885GRIN3B 2671/4885 |
| US-20080286377-A1 | ANTI-RESORPTIVE BONE CEMENTS AND ALLOGENEIC, AUTOGRAFIC, AND XENOGRAFIC BONE GRAFTS | SOST, BMP6, BMP2 | SIGMAR1 3945/4885GRIN2D 709/4885GRIN3B 473/4885 |
| US-20140323472-A1 | METHODS AND COMPOSITIONS FOR THE DELIVERY OF A THERAPEUTIC AGENT | TMEM205, NUP205, PIGS | SIGMAR1 1624/4885GRIN2D 4570/4885GRIN3B 2671/4885 |
| US-20080275030-A1 | alkoxy-polyethylene glycol or (ethylene oxide)1-10 adduct of methanol, ethanol, propanol, isopropanol and cyclopropanol; benzodiazepine; midazolam as a liqid therapeutic agent; less irritation to mucosal membrane when administered through Mucosal; enhances solubility of drug | OPRD1, DRD2, DRD1 | SIGMAR1 679/4885GRIN2D 103/4885GRIN3B 932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.